Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Humana
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$382.00
52 Haftanın En Yüksek Seviyesi	US$428.88
52 Haftanın En Düşük Seviyesi	US$163.11
Beta	0.74
1 Aylık Değişim	-4.50%
3 Aylık Değişim	25.62%
1 Yıllık Değişim	32.52%
3 Yıllık Değişim	-21.11%
5 Yıllık Değişim	-7.36%
Halka arzdan bu yana değişim	31,943.35%

Son Haberler & Güncellemeler

Anlatı Güncellemesi • Aug 07

HUM: Medicare Advantage Cost Trend Moderation Will Restore Margins Through 2028

Humana's analyst price target has moved from $502 to $513 as analysts point to improving visibility on Medicare Advantage cost trends, margin recovery potential, and a series of higher long term earnings estimates across multiple research firms. Analyst Commentary Recent research on Humana shows a cluster of more constructive views, with many bullish analysts pointing to Medicare Advantage cost trends, margin recovery potential, and longer term earnings power as key considerations for valuation.

Recent updates

Anlatı Güncellemesi • Aug 07

HUM: Medicare Advantage Cost Trend Moderation Will Restore Margins Through 2028

Seeking Alpha • Jul 29

Humana Q2 Earnings Review: Management Tight-Lipped, But Recovery Still On Track

Summary Humana Inc. targets a sustainable 3% pre-tax margin by 2028, focusing on Medicare Advantage plan quality and operational efficiency. Despite robust revenue growth, HUM’s profit margins have sharply declined, with Q2 2026 pre-tax margin at 1.8%, down from 6.7% in 2020. Management remains committed to margin recovery via improved Stars ratings, cost reductions, and selective plan exits, aiming for top-quartile performance. I maintain a Buy-the-Dip stance, though near-term volatility is likely as HUM forecasts negative Q3 EPS and a higher benefit ratio. Read the full article on Seeking Alpha

Anlatı Güncellemesi • Jul 23

HUM: Medicare Advantage Cost Trend Moderation Will Rebuild Margins And Earnings Power

The analyst price target for Humana has been revised higher from $441.00 to $502.00, supported by analysts citing moderating Medicare Advantage cost trends, improved confidence in margin recovery and earnings risk, and a willingness to apply a higher future P/E multiple to the stock. Analyst Commentary Recent research on Humana points to a clear shift toward more constructive sentiment, with a series of upward price target revisions and select rating upgrades highlighting improving confidence in Medicare Advantage trends, margin recovery potential, and earnings risk management.

Anlatı Güncellemesi • Jul 09

HUM: Medicare Advantage Rate And Stars Headwinds Will Restrain Margin Recovery

Humana's analyst fair value estimate has moved from $290.08 to $308.33 as analysts factor in higher target prices, supported by views of steadier medical cost trends, recovering Medicare Advantage margins, and a more stable policy backdrop for managed care. Analyst Commentary Recent Street research on Humana reflects a mix of confidence around the reset in Medicare Advantage economics and caution on execution risks over the next few years.

Anlatı Güncellemesi • Jun 25

HUM: Medicare Advantage Margin Recovery Will Restore Earnings Power And Future Multiple

Humana's fair value estimate has been raised from $371.06 to $441.00 as analysts factor in higher target prices, greater comfort with cost trends, and expectations for a more stable managed care policy backdrop that keeps attention on margin recovery and underlying earnings power. Analyst Commentary Recent research on Humana reflects a clear shift toward more constructive sentiment, with many bullish analysts lifting price targets and, in some cases, upgrading ratings as they reassess earnings power, margin recovery, and the policy backdrop for managed care.

Analiz Makalesi • Jun 16

Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally

Humana (HUM) has drawn fresh attention after recent trading, with the stock showing a mix of short term gains and longer term declines that raises questions about how investors currently view its valuation. See our latest analysis for Humana. Recent trading has pushed Humana’s share price to $380.26, with a 30 day share price return of 24.63% and a 1 year total shareholder return of 64.10%. However, 3 and 5 year total shareholder returns remain in decline, suggesting momentum has recently...

Anlatı Güncellemesi • Jun 08

HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins

Humana's updated analyst price target has moved higher from about $210 to roughly $290, as analysts point to muted medical cost trends, potential Medicare Advantage margin recovery, and company specific Stars improvement as key supports for earnings power. Analyst Commentary Recent research shows a clear reset higher in Humana's valuation framework, with multiple firms lifting price targets and, in some cases, upgrading ratings as they reassess earnings power tied to medical cost trends and Medicare Advantage margins.

Anlatı Güncellemesi • May 25

HUM: Medicare Advantage Margin Recovery Will Support Future Multiple Repricing

Humana's updated analyst price target of about $371, up from roughly $322, reflects analysts' focus on stabilizing managed care trends, expectations around Medicare Advantage margin recovery, and a shift to a slightly higher discount rate and profit margin in the underlying assumptions. Analyst Commentary Recent Street research on Humana centers on how quickly Medicare Advantage margins might stabilize, how medical loss ratios track against company targets, and what that could mean for valuation as managed care trends settle.

Anlatı Güncellemesi • May 03

HUM: Medicare Advantage Margin Execution Will Support Future Multiple Repricing

Humana's updated fair value estimate has moved from $302.11 to $322.19 as analysts adjust price targets higher across multiple firms, citing recent research that reflects revised revenue growth, margin expectations, and a higher assumed future P/E of 14.99. Analyst Commentary Recent Street research around Humana has shifted from sharp cuts earlier in the year to a cluster of higher price targets more recently.

Anlatı Güncellemesi • Apr 19

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Uncertainty

Humana's updated analyst price target edges slightly lower to about $210, as analysts balance recent target cuts tied to Medicare Advantage margin concerns with more recent upward revisions that reflect adjusted models, a modestly lower discount rate, and a slightly different profit margin and forward P/E outlook. Analyst Commentary Recent Street research on Humana reflects a split view, with some analysts revising price targets higher after updating models, while others remain cautious following earlier target cuts and rating downgrades tied to Medicare Advantage margins and CMS rate decisions.

Anlatı Güncellemesi • Apr 04

HUM: Medicare Advantage Margin Recovery Will Drive Future Repricing Potential

Humana's updated analyst price target has shifted down from $348.00 to about $302.11, as analysts factor in lower target ranges across the Street, a higher discount rate, and cautious views on Medicare Advantage margins and earnings visibility. Analyst Commentary Recent Street research on Humana reflects a broadly cautious stance, with several firms cutting price targets and reassessing Medicare Advantage earnings power.

Anlatı Güncellemesi • Mar 21

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Headwinds

Humana's updated analyst price target has been trimmed by about $12 to $212.17, as analysts factor in more cautious assumptions around Medicare Advantage margins, earnings guidance, and recent sector wide target cuts following Q4 results and regulatory news. Analyst Commentary Recent research on Humana reflects a clear reset in expectations, with price targets moving lower and ratings clustered around neutral.

Anlatı Güncellemesi • Mar 07

HUM: Medicare Advantage Margin Recovery Will Drive Future Upside Potential

Our updated Humana fair value estimate moves from $287.38 to $223.88, reflecting analysts' lower price targets across the Street as they factor in uncertainty around Medicare Advantage margin improvement, EPS guidance drivers, and the profitability of recent membership growth. Analyst Commentary Recent Street research around Humana has turned more cautious, with multiple firms cutting price targets and some shifting to more neutral stances.

Anlatı Güncellemesi • Feb 21

HUM: Medicare Advantage Margin Uncertainty Will Drive A Prolonged Earnings Reset

Humana's analyst fair value estimate has been reset from about $199.74 to $146.00. This reflects a broad wave of lower price targets as analysts factor in updated EPS guidance, Medicare Advantage margin uncertainty, and recent model revisions after Q4 results and regulatory developments.

Anlatı Güncellemesi • Feb 07

HUM: Policy And Margin Headwinds Will Shape A Gradual Recovery Path

Narrative Update on Humana The analyst price target for Humana has been reduced by about $18.75. Analysts point to recent downgrades, cautious reactions to CMS rate developments, and more conservative margin assumptions, even as they acknowledge potential longer term sector recovery drivers.

Analiz Makalesi • Feb 05

Humana Inc. (NYSE:HUM) Might Not Be As Mispriced As It Looks After Plunging 30%

Humana Inc. ( NYSE:HUM ) shareholders won't be pleased to see that the share price has had a very rough month, dropping...

Anlatı Güncellemesi • Jan 24

HUM: Margin And Policy Uncertainty Will Drive A More Cautious Outlook

Narrative Update Analysts have trimmed their price expectations for Humana, with the updated fair value estimate moving from about US$224 to roughly US$218. This reflects a higher discount rate, more cautious profit margin assumptions, and a lower future P/E multiple, even though modeled revenue growth is higher and recent research views are a mix of supportive and more restrained perspectives.

Anlatı Güncellemesi • Jan 08

HUM: Legal Appeals And Margin Recovery Prospects Will Shape Balanced Outlook

Humana's updated analyst price target has edged down by about $1 to roughly $287. Analysts are balancing slightly higher long term revenue and margin assumptions with mixed ratings that range from Sell to Outperform across recent research.

Analiz Makalesi • Dec 19

Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...

Anlatı Güncellemesi • Dec 14

HUM: Legal Appeals And Star Ratings Will Shape Balanced Outlook Ahead

Analysts have modestly increased Humana's fair value estimate by about $2 to roughly $288, reflecting slightly stronger projected revenue growth and improved earnings visibility, even as they incorporate more conservative sector margin assumptions and ongoing concerns about Medicare Advantage and Medicaid cyclicality. Analyst Commentary Recent Street research paints a mixed picture for Humana, with modest upside to fair value supported by improving earnings visibility, but tempered by meaningful concerns around Medicare Advantage dynamics, contract diversification efforts, and broader managed care cyclicality.

Analiz Makalesi • Dec 05

Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885

Humana Inc.'s ( NYSE:HUM ) investors are due to receive a payment of $0.885 per share on 30th of January. This payment...

Anlatı Güncellemesi • Nov 30

HUM: Shares Should Rebound As Legal Efforts Progress On Medicare Bonus Cuts

Humana's analyst price target has been modestly reduced from $288.46 to $286.63. Analysts are factoring in more conservative margin assumptions following recent quarterly results and updated evaluations of the company's revenue growth and profitability outlook.

Analiz Makalesi • Nov 16

Humana (NYSE:HUM) Has Announced A Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...

Anlatı Güncellemesi • Nov 15

HUM: Confidence Will Increase As Medicare Advantage Star Ratings Recover

Humana's analyst price target has been revised lower by approximately $7 to $288.46. Analysts cite a more cautious outlook on margins and an uneven recovery in Medicare Advantage profitability.

Analiz Makalesi • Nov 13

Humana's (NYSE:HUM) Conservative Accounting Might Explain Soft Earnings

Investors were disappointed with the weak earnings posted by Humana Inc. ( NYSE:HUM ). However, our analysis suggests...

Analiz Makalesi • Nov 02

Humana (NYSE:HUM) Will Pay A Dividend Of $0.885

The board of Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend on the 30th of January, with investors...

Anlatı Güncellemesi • Nov 01

HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook

Humana's analyst price target increased slightly, rising by approximately $0.83 to $295.38. Analysts cite mixed dynamics in Medicare Advantage star ratings and improving earnings visibility as factors supporting cautious optimism.

Anlatı Güncellemesi • Oct 18

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana’s analyst price target increased slightly to $294.54 from $292.87. Analysts cite improved earnings visibility and the stability of Medicare Advantage star ratings as supporting factors for the upward revision.

Anlatı Güncellemesi • Oct 04

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana's analyst price target has fallen from approximately $299 to $293 per share, as analysts cite ongoing challenges in Medicare Advantage star ratings and a more cautious growth outlook. This comes despite recent plan diversification efforts.

Anlatı Güncellemesi • Sep 05

AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery

Humana’s modestly higher fair value reflects improving investor sentiment, positive management commentary on future plan positioning, raised earnings guidance, and incremental legislative benefits, offset by some caution around interest rates and policy uncertainty, resulting in the consensus analyst price target rising slightly from $293.05 to $294.86. Analyst Commentary Improved investor sentiment and sector group valuations suggest estimates may have bottomed, with upcoming catalysts including government budget deals, Medicare Advantage and ACA pricing, and star ratings for future plans.

Analiz Makalesi • Aug 26

Humana (NYSE:HUM) Has Affirmed Its Dividend Of $0.885

Humana Inc. ( NYSE:HUM ) will pay a dividend of $0.885 on the 31st of October. The dividend yield is 1.2% based on this...

Hissedar Getirileri

	HUM	US Healthcare	US Pazar
7D	2.5%	-0.4%	-0.3%
1Y	32.5%	24.7%	19.9%

Getiri vs. Endüstri: HUM geçen yıl % 24.7 oranında getiri sağlayan US Healthcare sektörünü aştı.

Getiri vs Piyasa: HUM geçen yıl % 19.9 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is HUM's price volatile compared to industry and market?
HUM volatility
HUM Average Weekly Movement	5.5%
Healthcare Industry Average Movement	7.3%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: HUM son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: HUM 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1961	67,060	Jim Rechtin	www.humana.com

Humana Inc. Amerika Birleşik Devletleri'nde tıbbi ve özel sigorta ürünleri sunmaktadır. Insurance ve CenterWell olmak üzere iki segmentte faaliyet göstermektedir. Insurance segmenti, sağlık programları, kronik bakım yönetimi ve bakım koordinasyonu dahil olmak üzere sağlık sigortası yardımlarını içeren bireysel Medicare Advantage ürünleri; bireysel Medicare bağımsız reçeteli ilaç ürünleri (PDP); grup Medicare avantajı ve Medicare bağımsız PDP; Medicare ekleri; diş, görme, hayat ve maluliyetten oluşan özel ve yardımcı sigorta; ve aktif görevdeki ve emekli askeri personel ve bakmakla yükümlü oldukları kişiler ile eczane fayda yöneticileri için sağlık hizmetleri düzenlemek üzere idari hizmetler sunmaktadır.

Humana Inc. Temel Bilgiler Özeti

Humana'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
HUM temel i̇stati̇sti̇kler
Piyasa değeri	US$46.15b
Kazançlar(TTM)	US$1.28b
Gelir(TTM)	US$145.68b

35.9x

F/K Oranı

0.3x

P/S Oranı

HUM aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
HUM gelir tablosu (TTM)
Gelir	US$145.68b
Gelir Maliyeti	US$125.79b
Brüt Kâr	US$19.89b
Diğer Giderler	US$18.61b
Kazançlar	US$1.28b

Son Raporlanan Kazançlar

Jun 30, 2026

Sonraki Kazanç Tarihi

Nov 06, 2026

Hisse başına kazanç (EPS)	10.65
Brüt Marj	13.65%
Net Kâr Marjı	0.88%
Borç/Özkaynak Oranı	76.5%

HUM uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.9%

Mevcut Temettü Verimi

33%

Ödeme Oranı

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/18 04:36
Gün Sonu Hisse Fiyatı	2026/08/18 00:00
Kazançlar	2026/06/30
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Humana Inc. 37 Bu analistlerden 21, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Toung	Argus Research Company
Hua Ha	Baird
Andrew Mok	Barclays

Humana (HUM) Hisse Özeti

Ödüller

Risk Analizi

Analyst Price Targets

HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook

Aging Population And Tech Will Shape Long-Term Medicare Care

Reforms And Rising Costs Will Erode Medicare Margins

Top Community Narratives

Humana Faces Rising Medicare Scrutiny as Compliance Rules Tighten

Top Community Narratives

Humana Faces Rising Medicare Scrutiny as Compliance Rules Tighten

Top Analyst Narratives

HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook

Aging Population And Tech Will Shape Long-Term Medicare Care

Reforms And Rising Costs Will Erode Medicare Margins

Humana Inc. Rakipler

Elevance Health

HealthEquity

UnitedHealth Group

Progyny

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Humana Appoints James P Holland to Lead Medicaid Division Covering 1.6 Million Members

Humana Inc. Announces Appointment of James P. Holland to Senior Vice President and President of Medicaid, Effective August 17, 2026

HUM: Medicare Advantage Cost Trend Moderation Will Restore Margins Through 2028

Humana Subsidiary iCare Wins Southeast Wisconsin Care Contracts Expanding Regional Reach

Humana to Exit More Medicare Advantage Plans in 2027 Impacting 600,000 Members

Second quarter 2026 earnings: EPS misses analyst expectations

Recent updates

Humana Appoints James P Holland to Lead Medicaid Division Covering 1.6 Million Members

Humana Inc. Announces Appointment of James P. Holland to Senior Vice President and President of Medicaid, Effective August 17, 2026

HUM: Medicare Advantage Cost Trend Moderation Will Restore Margins Through 2028

Humana Subsidiary iCare Wins Southeast Wisconsin Care Contracts Expanding Regional Reach

Humana to Exit More Medicare Advantage Plans in 2027 Impacting 600,000 Members

Second quarter 2026 earnings: EPS misses analyst expectations

Humana Inc. Revises Earnings Guidance for the Year Ending December 31, 2026

Humana Q2 Earnings Review: Management Tight-Lipped, But Recovery Still On Track

HUM: Medicare Advantage Cost Trend Moderation Will Rebuild Margins And Earnings Power

Price target increased by 14% to US$347

HUM: Medicare Advantage Rate And Stars Headwinds Will Restrain Margin Recovery

Humana Chosen for Statewide Illinois Medicaid Managed Care Program Starting 2027

HUM: Medicare Advantage Margin Recovery Will Restore Earnings Power And Future Multiple

Upcoming dividend of US$0.89 per share

Humana Stock Gains Statewide Illinois Medicaid Contract Expanding Reach to 102 Counties

Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally

Humana Draws Investor Interest on Growth Outlook Despite Stock Decline and Margin Challenges

Price target increased by 8.8% to US$297

HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins

Price target increased by 9.2% to US$269

HUM: Medicare Advantage Margin Recovery Will Support Future Multiple Repricing

Investor sentiment improves as stock rises 16%

HUM: Medicare Advantage Margin Execution Will Support Future Multiple Repricing

Price target increased by 12% to US$236

First quarter 2026 earnings: EPS misses analyst expectations

Humana Inc. Revises Earnings Guidance for the Year Ending December 31, 2026

Dividend of US$0.89 announced

CenterWell Introduces the Fulfillment Index

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Uncertainty

Humana Inc. Declares Quarterly Cash Dividend, Payable on July 31, 2026

Humana Inc. Elects Robert S. Field to the Board of Directors, Effective April 10, 2026

President of CenterWell exercised options and sold US$70k worth of stock

HUM: Medicare Advantage Margin Recovery Will Drive Future Repricing Potential

Humana Inc. to Report Q1, 2026 Results on Apr 29, 2026

HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Headwinds

Upcoming dividend of US$0.89 per share

Humana Inc., Annual General Meeting, Apr 16, 2026

HUM: Medicare Advantage Margin Recovery Will Drive Future Upside Potential

Humana Inc. Introduces New Value-Based Cardiology Care Partnerships for Medicare Advantage Members

Fourth quarter dividend of US$0.89 announced

New minor risk - Earnings quality

HUM: Medicare Advantage Margin Uncertainty Will Drive A Prolonged Earnings Reset

Humana Inc. Declares Quarterly Cash Dividend, Payable on April 24, 2026

Price target decreased by 12% to US$249

Humana Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026

HUM: Policy And Margin Headwinds Will Shape A Gradual Recovery Path

Humana Inc. (NYSE:HUM) Might Not Be As Mispriced As It Looks After Plunging 30%

Humana Inc. (NYSE:HUM) completed the acquisition of Familiehjelpgruppen As.

Investor sentiment deteriorates as stock falls 22%

HUM: Margin And Policy Uncertainty Will Drive A More Cautious Outlook

Humana Inc. to Report Q4, 2025 Results on Feb 11, 2026